Brooklyn ImmunoTherapeutics reports FY2021 net loss of $122.3M; cash $17M

Ernexa Therapeutics Inc.

2022-Q1 EPS reported -$0.17 vs consensus -$1071.00 ▲ beat (+100.0%)

Net loss $122.3M for FY2021 vs $26.5M in 2020; Q4 loss $8.5M vs $21.5M.
Operating expenses $113.6M, including $80.5M acquired IPR&D from Novellus deal.
Cash $17.0M at Dec 31, 2021, up from $1.6M a year ago; raised $52M via equity sales.
Completed Novellus acquisition in July 2021; new executives appointed.
Phase 2b head & neck cancer trial readout for IRX-2 expected Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.